Three off-the-shelf mRNA therapies join intismeran autogene.

Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.

New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.

Antibody-drug conjugates hitting this target abound.

April saw a checkpoint inhibitor bonanza for Bristol and Akeso.

An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.

A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.

Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.